
Michal Sarnecki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/973830/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nature Medicine, 2020, 26, 498-501.	30.7	43
2	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. Journal of Infectious Diseases, 2018, 218, 633-644.	4.0	35
3	Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: A 20-year follow-up study. Vaccine, 2017, 35, 1448-1454.	3.8	26
4	Comparative Efficacy, Safety and Immunogenicity of Hepavax-Gene TF and Engerix-B Recombinant Hepatitis B Vaccines in Neonates in China. Pediatric Infectious Disease Journal, 2017, 36, 94-101.	2.0	2
5	Long-term Serologic Follow-up of Children Vaccinated with a Pediatric Formulation of Virosomal Hepatitis A Vaccine Administered With Routine Childhood Vaccines at 12–15 Months of Age. Pediatric Infectious Disease Journal, 2016, 35, e220-e228.	2.0	11
6	The Safety and Immunogenicity of Two Hepatitis B Vaccine Formulations (Thiomersal-free and) Tj ETQq0 0 0 rgBT 79-83.	/Overlock 2.0	10 Tf 50 54 2
7	Long-term Antibody Persistence in Children After Vaccination With the Pediatric Formulation of an Aluminum-free Virosomal Hepatitis A Vaccine. Pediatric Infectious Disease Journal, 2015, 34, e85-e91.	2.0	13
8	Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India. Human Vaccines and Immunotherapeutics, 2014, 10, 2089-2097.	3.3	10
9	Development and performance characteristics of novel codeâ€based algorithms to identify invasive <scp> <i>Escherichia coli</i> </scp> disease. Pharmacoepidemiology and Drug Safety, 0, , .	1.9	2